Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.9650
-0.0550 (-5.39%)
Aug 14, 2025, 11:51 AM - Market open
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jared Kelly |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403-670-7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| Andrew P. Aromando | Chief Business Officer |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 6-K | Report of foreign issuer |
| Aug 8, 2025 | 6-K | Report of foreign issuer |
| Aug 8, 2025 | 6-K | Report of foreign issuer |
| Aug 8, 2025 | 6-K | Report of foreign issuer |
| Aug 8, 2025 | 6-K | Report of foreign issuer |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 23, 2025 | 6-K | Report of foreign issuer |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 16, 2025 | 6-K | Report of foreign issuer |